193 related articles for article (PubMed ID: 31820437)
1. Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients.
McPhail BT; Emoto C; Fukuda T; Butler D; Wiles JR; Akinbi H; Vinks AA
J Clin Pharmacol; 2020 Apr; 60(4):453-465. PubMed ID: 31820437
[TBL] [Abstract][Full Text] [Related]
2. Methadone dosing strategies in preterm neonates can be simplified.
van Donge T; Samiee-Zafarghandy S; Pfister M; Koch G; Kalani M; Bordbar A; van den Anker J
Br J Clin Pharmacol; 2019 Jun; 85(6):1348-1356. PubMed ID: 30805946
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study.
Wiles JR; Isemann B; Mizuno T; Tabangin ME; Ward LP; Akinbi H; Vinks AA
J Pediatr; 2015 Dec; 167(6):1214-20.e3. PubMed ID: 26364984
[TBL] [Abstract][Full Text] [Related]
4. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.
Yang F; Tong X; McCarver DG; Hines RN; Beard DA
J Pharmacokinet Pharmacodyn; 2006 Aug; 33(4):485-518. PubMed ID: 16758333
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome.
van Hoogdalem MW; Johnson TN; McPhail BT; Kamatkar S; Wexelblatt SL; Ward LP; Christians U; Akinbi HT; Vinks AA; Mizuno T
Clin Pharmacol Ther; 2022 Feb; 111(2):496-508. PubMed ID: 34679189
[TBL] [Abstract][Full Text] [Related]
6. Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches.
McPhail BT; Emoto C; Butler D; Fukuda T; Akinbi H; Vinks AA
J Clin Pharmacol; 2021 Jul; 61(7):857-870. PubMed ID: 33382111
[TBL] [Abstract][Full Text] [Related]
7. Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome.
Young ME; Hager SJ; Spurlock D
Am J Health Syst Pharm; 2015 Dec; 72(23 Suppl 3):S162-7. PubMed ID: 26582303
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.
Ng CM; Dombrowsky E; Lin H; Erlich ME; Moody DE; Barrett JS; Kraft WK
Pharmacotherapy; 2015 Jul; 35(7):670-80. PubMed ID: 26172282
[TBL] [Abstract][Full Text] [Related]
9. Association between intrapartum fetal heart rate patterns and neonatal abstinence syndrome in methadone exposed neonates.
Leeman LM; Brown SA; Albright B; Skipper B; Hsi A; Rayburn WF
J Matern Fetal Neonatal Med; 2011 Jul; 24(7):955-9. PubMed ID: 21142769
[TBL] [Abstract][Full Text] [Related]
10. Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes.
de Castro A; Jones HE; Johnson RE; Gray TR; Shakleya DM; Huestis MA
Ther Drug Monit; 2011 Aug; 33(4):443-52. PubMed ID: 21743375
[TBL] [Abstract][Full Text] [Related]
11. Cohort Analysis of a Pharmacokinetic-Modeled Methadone Weaning Optimization for Neonatal Abstinence Syndrome.
Hall ES; Meinzen-Derr J; Wexelblatt SL
J Pediatr; 2015 Dec; 167(6):1221-5.e1. PubMed ID: 26477866
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a clinical pathway with methadone treatment protocol for treatment of neonatal abstinence syndrome following in utero drug exposure to substances of abuse*.
Bhatt-Mehta V; Ng CM; Schumacher RE
Pediatr Crit Care Med; 2014 Feb; 15(2):162-9. PubMed ID: 24141658
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics.
van Hoogdalem MW; McPhail BT; Hahn D; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):87-103. PubMed ID: 33049155
[TBL] [Abstract][Full Text] [Related]
14. Neonatal abstinence syndrome: Historical perspective, current focus, future directions.
Jones HE; Fielder A
Prev Med; 2015 Nov; 80():12-7. PubMed ID: 26232620
[TBL] [Abstract][Full Text] [Related]
15. The relationship between gestational age and the severity of neonatal abstinence syndrome.
Gibson KS; Stark S; Kumar D; Bailit JL
Addiction; 2017 Apr; 112(4):711-716. PubMed ID: 27886650
[TBL] [Abstract][Full Text] [Related]
16. Opioid neonatal abstinence syndrome: controversies and implications for practice.
Wolff K; Perez-Montejano R
Curr Drug Abuse Rev; 2014; 7(1):44-58. PubMed ID: 25323126
[TBL] [Abstract][Full Text] [Related]
17. Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers.
Mactier H; McLaughlin P; Gillis C; Osselton MD
Am J Perinatol; 2017 Jul; 34(9):918-921. PubMed ID: 28320034
[No Abstract] [Full Text] [Related]
18. Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome.
Metzger IF; Thomas AE; Evrard CA; Jones DR; Masters AR; Haas DM; Haneline LS; Quinney SK
Am J Perinatol; 2021 Jul; 38(9):968-975. PubMed ID: 32052397
[TBL] [Abstract][Full Text] [Related]
19. A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome.
Hall ES; Isemann BT; Wexelblatt SL; Meinzen-Derr J; Wiles JR; Harvey S; Akinbi HT
J Pediatr; 2016 Mar; 170():39-44.e1. PubMed ID: 26703873
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial.
Davis JM; Shenberger J; Terrin N; Breeze JL; Hudak M; Wachman EM; Marro P; Oliveira EL; Harvey-Wilkes K; Czynski A; Engelhardt B; D'Apolito K; Bogen D; Lester B
JAMA Pediatr; 2018 Aug; 172(8):741-748. PubMed ID: 29913015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
